Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity

Toxicology in Vitro

Volumn 26, Issue 3, 2012, Pages 373-385

  Van Summeren, Anke ^a,b   Renes, Johan ^a,b   Van Delft, Joost H M ^a,b   Kleinjans, Jos C S ^a,b   Mariman, Edwin C M ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Netherlands Toxicogenomic Centre (NTC)   (Netherlands)

Author keywords

Biomarkers; Hepatotoxicity; In vitro; In vivo; Liver; Proteomics

Indexed keywords

BIOLOGICAL MARKER; PROTEOME;

CELL FRACTIONATION; ENDOPLASMIC RETICULUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; TANDEM MASS SPECTROMETRY; TOXIC HEPATITIS; TOXICITY TESTING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DRUG DESIGN; DRUG-INDUCED LIVER INJURY; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEOMICS; TOXICITY TESTS;

ANIMALIA;

EID: 84857684723     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2012.01.012     Document Type: Review

References (80)

1. Aitman T.J., Critser J.K., Cuppen E., Dominiczak A., Fernandez-Suarez X.M., Flint J., Gauguier D., Geurts A.M., Gould M., Harris P.C., Holmdahl R., Hubner N., Izsvak Z., Jacob H.J., Kuramoto T., Kwitek A.E., Marrone A., Mashimo T., Moreno C., Mullins J., Mullins L., Olsson T., Pravenec M., Riley L., Saar K., Serikawa T., Shull J.D., Szpirer C., Twigger S.N., Voigt B., Worley K. Progress and prospects in rat genetics: a community view. Nat. Genet. 2008, 40:516-522.
2. Alvergnas M., Rouleau A., Lucchi G., Heyd B., Ducoroy P., Richert L., Martin H. Proteomic mapping of bezafibrate-treated human hepatocytes in primary culture using two-dimensional liquid chromatography. Toxicol. Lett. 2011, 201:123-129.
3. Amacher D.E. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicol. Appl. Pharmacol. 2010, 245:134-142.
4. Bailey S.M., Andringa K.K., Landar A., Darley-Usmar V.M. Proteomic approaches to identify and characterize alterations to the mitochondrial proteome in alcoholic liver disease. Methods Mol. Biol. 2008, 447:369-380.
5. Barrier M., Mirkes P.E. Proteomics in developmental toxicology. Reprod. Toxicol. 2005, 19:291-304.
6. Boitier E., Amberg A., Barbie V., Blichenberg A., Brandenburg A., Gmuender H., Gruhler A., McCarthy D., Meyer K., Riefke B., Raschke M., Schoonen W., Sieber M., Suter L., Thomas C.E., Sajot N. A comparative integrated transcript analysis and functional characterization of differential mechanisms for induction of liver hypertrophy in the rat. Toxicol. Appl. Pharmacol. 2011, 252:85-96.
7. Brunet S., Thibault P., Gagnon E., Kearney P., Bergeron J.J., Desjardins M. Organelle proteomics: looking at less to see more. Trends Cell Biol. 2003, 13:629-638.
8. Choi S., Park S.Y., Jeong J., Cho E., Phark S., Lee M., Kwak D., Lim J.Y., Jung W.W., Sul D. Identification of toxicological biomarkers of di(2-ethylhexyl) phthalate in proteins secreted by HepG2 cells using proteomic analysis. Proteomics 2010, 10:1831-1846.
9. Craig A., Sidaway J., Holmes E., Orton T., Jackson D., Rowlinson R., Nickson J., Tonge R., Wilson I., Nicholson J. Systems toxicology: integrated genomic, proteomic and metabonomic analysis of methapyrilene induced hepatotoxicity in the rat. J. Proteome Res. 2006, 5:1586-1601.
10. Donato M.T., Lahoz A., Castell J.V., Gomez-Lechon M.J. Cell lines: a tool for in vitro drug metabolism studies. Curr. Drug Metab. 2008, 9:1-11.
11. Dunn J.C., Tompkins R.G., Yarmush M.L. Long-term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol. Prog. 1991, 7:237-245.
12. Erlinger S. Drug-induced cholestasis. J. Hepatol. 1997, 26(Suppl. 1):1-4.
13. Farkas D., Tannenbaum S.R. Characterization of chemically induced hepatotoxicity in collagen sandwiches of rat hepatocytes. Toxicol. Sci. 2005, 85:927-934.
14. Farkas D., Bhat V.B., Mandapati S., Wishnok J.S., Tannenbaum S.R. Characterization of the secreted proteome of rat hepatocytes cultured in collagen sandwiches. Chem. Res. Toxicol. 2005, 18:1132-1139.
15. Fielden M.R., Brennan R., Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 2007, 99:90-100.
16. Fountoulakis M., Berndt P., Boelsterli U.A., Crameri F., Winter M., Albertini S., Suter L. Two-dimensional database of mouse liver proteins: changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 2000, 21:2148-2161.
17. Fujii K., Kondo T., Yokoo H., Okano T., Yamada M., Yamada T., Iwatsuki K., Hirohashi S. Database of two-dimensional polyacrylamide gel electrophoresis of proteins labeled with CyDye DIGE Fluor saturation dye. Proteomics 2006, 6:1640-1653.
18. Galeva N., Altermann M. Comparison of one-dimensional and two-dimensional gel electrophoresis as a separation tool for proteomic analysis of rat liver microsomes: cytochromes P450 and other membrane proteins. Proteomics 2002, 2:713-722.
19. Gao J., Ann Garulacan L., Storm S.M., Hefta S.A., Opiteck G.J., Lin J.H., Moulin F., Dambach D.M. Identification of in vitro protein biomarkers of idiosyncratic liver toxicity. Toxicol. In Vitro 2004, 18:533-541.
20. Gorg A., Weiss W., Dunn M.J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4:3665-3685.
21. Greenhough S., Medine C.N., Hay D.C. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology 2010, 278:250-255.
22. Guyot C., Lepreux S., Combe C., Doudnikoff E., Bioulac-Sage P., Balabaud C., Desmouliere A. Hepatic fibrosis and cirrhosis: the (myo)fibroblastic cell subpopulations involved. Int. J. Biochem. Cell Biol. 2006, 38:135-151.
23. Hartung T. Toxicology for the twenty-first century. Nature 2009, 460:208-212.
24. Heijne W.H., Stierum R.H., Slijper M., van Bladeren P.J., van Ommen B. Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. Biochem. Pharmacol. 2003, 65:857-875.
25. Hughes C.S., Nuhn A.A., Postovit L.M., Lajoie G.A. Proteomics of human embryonic stem cells. Proteomics 2011, 11:675-690.
26. Jennen D.G., Gaj S., Giesbertz P.J., van Delft J.H., Evelo C.T., Kleinjans J.C. Biotransformation pathway maps in WikiPathways enable direct visualization of drug metabolism related expression changes. Drug Discov Today 2010, 15:851-858.
27. Jia N., Liu X., Wen J., Qian L., Qian X., Wu Y., Fan G. A proteomic method for analysis of CYP450s protein expression changes in carbon tetrachloride induced male rat liver microsomes. Toxicology 2007, 237:1-11.
28. Karp N.A., Feret R., Rubtsov D.V., Lilley K.S. Comparison of DIGE and post-stained gel electrophoresis with both traditional and SameSpots analysis for quantitative proteomics. Proteomics 2008, 8:948-960.
29. Kienhuis A.S., Wortelboer H.M., Maas W.J., van Herwijnen M., Kleinjans J.C., van Delft J.H., Stierum R.H. A sandwich-cultured rat hepatocyte system with increased metabolic competence evaluated by gene expression profiling. Toxicol. In Vitro 2007, 21:892-901.
30. Kienhuis A.S., van de Poll M.C., Dejong C.H., Gottschalk R., van Herwijnen M., Boorsma A., Kleinjans J.C., Stierum R.H., van Delft J.H. A toxicogenomics-based parallelogram approach to evaluate the relevance of coumarin-induced responses in primary human hepatocytes in vitro for humans in vivo. Toxicol. In Vitro 2009, 23:1163-1169.
31. Kienhuis A.S., Bessems J.G., Pennings J.L., Driessen M., Luijten M., van Delft J.H., Peijnenburg A.A., van der Ven L.T. Application of toxicogenomics in hepatic systems toxicology for risk assessment: acetaminophen as a case study. Toxicol. Appl. Pharmacol. 2011, 250:96-107.
32. Kikkawa R., Yamamoto T., Fukushima T., Yamada H., Horii I. Investigation of a hepatotoxicity screening system in primary cell cultures -" what biomarkers would need to be addressed to estimate toxicity in conventional and new approaches?" J. Toxicol. Sci. 2005, 30:61-72.
33. Kikkawa R., Fujikawa M., Yamamoto T., Hamada Y., Yamada H., Horii I. In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system. J. Toxicol. Sci. 2006, 31:23-34.
34. Kleno T.G., Leonardsen L.R., Kjeldal H.O., Laursen S.M., Jensen O.N., Baunsgaard D. Mechanisms of hydrazine toxicity in rat liver investigated by proteomics and multivariate data analysis. Proteomics 2004, 4:868-880.
35. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000, 356:1587-1591.
36. Koen Y.M., Gogichaeva N.V., Alterman M.A., Hanzlik R.P. A proteomic analysis of bromobenzene reactive metabolite targets in rat liver cytosol in vivo. Chem. Res. Toxicol. 2007, 20:511-519.
37. Lavoie C., Paiement J. Topology of molecular machines of the endoplasmic reticulum: a compilation of proteomics and cytological data. Histochem. Cell Biol. 2008, 129:117-128.
38. Lewis J.A., Dennis W.E., Hadix J., Jackson D.A. Analysis of secreted proteins as an in vitro model for discovery of liver toxicity markers. J. Proteome Res. 2010, 9:5794-5802.
39. Low T.Y., Leow C.K., Salto-Tellez M., Chung M.C. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics 2004, 4:3960-3974.
40. Martinez S.M., Bradford B.U., Soldatow V.Y., Kosyk O., Sandot A., Witek R., Kaiser R., Stewart T., Amaral K., Freeman K., Black C., LeCluyse E.L., Ferguson S.S., Rusyn I. Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicity. Toxicol. Appl. Pharmacol. 2010, 249:208-216.
41. Matheis K.A., Com E., Gautier J.C., Guerreiro N., Brandenburg A., Gmuender H., Sposny A., Hewitt P., Amberg A., Boernsen O., Riefke B., Hoffmann D., Mally A., Kalkuhl A., Suter L., Dieterle F., Staedtler F. Cross-study and cross-omics comparisons of three nephrotoxic compounds reveal mechanistic insights and new candidate biomarkers. Toxicol. Appl. Pharmacol. 2011, 252:112-122.
42. Mathijs K., Kienhuis A.S., Brauers K.J., Jennen D.G., Lahoz A., Kleinjans J.C., van Delft J.H. Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab. Dispos. 2009, 37:1305-1311.
43. McBurney R.N., Hines W.M., Von Tungeln L.S., Schnackenberg L.K., Beger R.D., Moland C.L., Han T., Fuscoe J.C., Chang C.W., Chen J.J., Su Z., Fan X.H., Tong W., Booth S.A., Balasubramanian R., Courchesne P.L., Campbell J.M., Graber A., Guo Y., Juhasz P.J., Li T.Y., Lynch M.D., Morel N.M., Plasterer T.N., Takach E.J., Zeng C., Beland F.A. The liver toxicity biomarker study: phase I design and preliminary results. Toxicol. Pathol. 2009, 37:52-64.
44. Meneses-Lorente G., Guest P.C., Lawrence J., Muniappa N., Knowles M.R., Skynner H.A., Salim K., Cristea I., Mortishire-Smith R., Gaskell S.J., Watt A. A proteomic investigation of drug-induced steatosis in rat liver. Chem. Res. Toxicol. 2004, 17:605-612.
45. Meneses-Lorente G., Watt A., Salim K., Gaskell S.J., Muniappa N., Lawrence J., Guest P.C. Identification of early proteomic markers for hepatic steatosis. Chem. Res. Toxicol. 2006, 19:986-998.
46. Meng Z., Veenstra T.D. Targeted mass spectrometry approaches for protein biomarker verification 2011, J Proteomics.
47. Merrick B.A., Bruno M.E., Madenspacher J.H., Wetmore B.A., Foley J., Pieper R., Zhao M., Makusky A.J., McGrath A.M., Zhou J.X., Taylor J., Tomer K.B. Alterations in the rat serum proteome during liver injury from acetaminophen exposure. J. Pharmacol. Exp. Ther. 2006, 318:792-802.
48. Neilson K.A., Ali N.A., Muralidharan S., Mirzaei M., Mariani M., Assadourian G., Lee A., van Sluyter S.C., Haynes P.A. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 2011, 11:535-553.
49. Nie A.Y., McMillian M., Parker J.B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., Lord P.G. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 2006, 45:914-933.
50. Nisar S., Lane C.S., Wilderspin A.F., Welham K.J., Griffiths W.J., Patterson L.H. A proteomic approach to the identification of cytochrome P450 isoforms in male and female rat liver by nanoscale liquid chromatography-electrospray ionization-tandem mass spectrometry. Drug Metab. Dispos. 2004, 32:382-386.
51. Olson H., Betton G., Stritar J., Robinson D. The predictivity of the toxicity of pharmaceuticals in humans from animal data - an interim assessment. Toxicol. Lett. 1998, 102-103:535-538.
52. Pan C., Kumar C., Bohl S., Klingmueller U., Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol. Cell. Proteomics 2009, 8:443-450.
53. Pichard L., Raulet E., Fabre G., Ferrini J.B., Ourlin J.C., Maurel P. Human hepatocyte culture. Methods Mol. Biol. 2006, 320:283-293.
54. Reichen J., Berr F., Le M., Warren G.H. Characterization of calcium deprivation-induced cholestasis in the perfused rat liver. Am. J. Physiol. 1985, 249:G48-57.
55. Ruepp S.U., Tonge R.P., Shaw J., Wallis N., Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 2002, 65:135-150.
56. Rumack B.H. Acetaminophen hepatotoxicity: the first 35years. J. Toxicol. Clin. Toxicol. 2002, 40:3-20.
57. Sakamoto A., Matsumaru T., Ishiguro N., Schaefer O., Ohtsuki S., Inoue T., Kawakami H., Terasaki T. Reliability and robustness of simultaneous absolute quantification of drug transporters, cytochrome P450 enzymes, and udp-glucuronosyltranferases in human liver tissue by multiplexed MRM/selected reaction monitoring mode tandem mass spectrometry with nano-liquid chromatography. J. Pharm. Sci. 2011, 100:4037-4043.
58. Seglen P.O. Preparation of isolated rat liver cells. Methods Cell Biol. 1976, 13:29-83.
59. Seliskar M., Rozman D. Mammalian cytochromes P450-importance of tissue specificity. Biochim. Biophys. Acta 2007, 1770:458-466.
60. Slany A., Haudek V.J., Zwickl H., Gundacker N.C., Grusch M., Weiss T.S., Seir K., Rodgarkia-Dara C., Hellerbrand C., Gerner C. Cell characterization by proteome profiling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J. Proteome Res. 2010, 9:6-21.
61. Suter L., Schroeder S., Meyer K., Gautier J.C., Amberg A., Wendt M., Gmuender H., Mally A., Boitier E., Ellinger-Ziegelbauer H., Matheis K., Pfannkuch F. EU Framework 6 Project: Predictive Toxicology (PredTox)-overview and outcome. Toxicol. Appl. Pharmacol. 2010, 252:73-84.
62. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
63. Thome-Kromer B., Bonk I., Klatt M., Nebrich G., Taufmann M., Bryant S., Wacker U., Kopke A. Toward the identification of liver toxicity markers: a proteome study in human cell culture and rats. Proteomics 2003, 3:1835-1862.
64. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
65. Tolando R., Zanovello A., Ferrara R., Iley J.N., Manno M. Inactivation of rat liver cytochrome P450 (P450) by N,N-dimethylformamide and N,N-dimethylacetamide. Toxicol. Lett. 2001, 124:101-111.
66. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 2008, 21:84-92.
67. Van Summeren A., Renes J., Bouwman F.G., Noben J.P., van Delft J.H., Kleinjans J.C., Mariman E.C. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol. Sci. 2011, 120:109-122.
68. Venkatraman A., Landar A., Davis A.J., Chamlee L., Sanderson T., Kim H., Page G., Pompilius M., Ballinger S., Darley-Usmar V., Bailey S.M. Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. J. Biol. Chem. 2004, 279:22092-22101.
69. Wang K., Shindoh H., Inoue T., Horii I. Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J. Toxicol. Sci. 2002, 27:229-237.
70. Wang P., Mariman E., Keijer J., Bouwman F., Noben J.P., Robben J., Renes J. Profiling of the secreted proteins during 3T3-L1 adipocyte differentiation leads to the identification of novel adipokines. Cell. Mol. Life Sci. 2004, 61:2405-2417.
71. Wang Y., Yang B., Wu C., Zheng Z., Yuan Y., Hu Z., Ma H., Li S., Liao M., Wang Q. Plasma and liver proteomic analysis of 3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-1,3-2H-indol-2-one-induced hepatotoxicity in Wistar rats. Proteomics 2010, 10:2927-2941.
72. Waters M., Stasiewicz S., Merrick B.A., Tomer K., Bushel P., Paules R., Stegman N., Nehls G., Yost K.J., Johnson C.H., Gustafson S.F., Xirasagar S., Xiao N., Huang C.C., Boyer P., Chan D.D., Pan Q., Gong H., Taylor J., Choi D., Rashid A., Ahmed A., Howle R., Selkirk J., Tennant R., Fostel J. CEBS - Chemical Effects in Biological Systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res. 2008, 36:D892-900.
73. Weber L.W., Boll M., Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 2003, 33:105-136.
74. Wetmore B.A., Merrick B.A. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 2004, 32:619-642.
75. Wilm M. Quantitative proteomics in biological research. Proteomics 2009, 9:4590-4605.
76. Yamamoto T., Kikkawa R., Yamada H., Horii I. Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J. Toxicol. Sci. 2005, 30:213-227.
77. Yamamoto T., Kikkawa R., Yamada H., Horii I. Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J. Toxicol. Sci. 2006, 31:49-60.
78. Yamanaka H., Yakabe Y., Saito K., Sekijima M., Shirai T. Quantitative proteomic analysis of rat liver for carcinogenicity prediction in a 28-day repeated dose study. Proteomics 2007, 7:781-795.
79. Zgoda V., Tikhonova O., Viglinskaya A., Serebriakova M., Lisitsa A., Archakov A. Proteomic profiles of induced hepatotoxicity at the subcellular level. Proteomics 2006, 6:4662-4670.
80. Zwickl H., Traxler E., Staettner S., Parzefall W., Grasl-Kraupp B., Karner J., Schulte-Hermann R., Gerner C. A novel technique to specifically analyze the secretome of cells and tissues. Electrophoresis 2005, 26:2779-2785.